Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 82-87

  Stover, D G ^a   Reddy, V K ^a   Shyr, Y ^a   Savani, B N ^a   Reddy, N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

absolute lymphocyte count; auto SCT; diffuse large B cell lymphoma; early lymphocyte recovery; rituximab

Indexed keywords

RITUXIMAB;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; EARLY LYMPHOCYTE RECOVERY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84855728605     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.29     Document Type: Article

References (22)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 46-54.
3. Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49: 1890-1900.
4. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009; 15: 1455-1464.
5. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Moreb JS. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma. Bone Marrow Transplant 2003; 31: 1009-1013. (Pubitemid 36722413)
6. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
7. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008; 14: 807-816. (Pubitemid 351773157)
8. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454-2460. (Pubitemid 29368245)
9. Kim H, Sohn HJ, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37: 1037-1042.
10. Porrata LF, Gertz MA, Litzow MR, Lacy MQ, Dispenzieri A, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11: 1210-1218. (Pubitemid 40175773)
11. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291-298. (Pubitemid 38256560)
12. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416-4423. (Pubitemid 38745964)
13. Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantlecell lymphoma. Bone Marrow Transplant 2006; 37: 865-871.
14. Tiwari D, Gao F, Hidalgo J, Adkins DR, Vij R, DiPersio JF et al. Prognostic significance of early lymphocyte recovery after post-auto grafting administration of GM-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40: 671-675. (Pubitemid 47456481)
15. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell- lymphoma. Leuk Lymphoma 2008; 49: 1745-1751.
16. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ et al. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. Biol Blood Marrow Transplant 2010; 16: 376-383.
17. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 2008; 81: 448-453.
18. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471-1490. (Pubitemid 28406849)
19. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-783. (Pubitemid 38129532)
20. Lim SH, Zhang Y, Wang Z, Esler WV, Beggs D. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2005; 35: 207-208. (Pubitemid 40185940)
21. Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM. Loss of major his to compatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006; 108: 311-318. (Pubitemid 43990644)
22. Lee NR, Song EK, Jang KY, Choi HN, Moon WS. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008; 49: 247-256. (Pubitemid 351193916)